Lantern Pharma's first TNBC site and Taiwan start meet a CEO exit and a $4.0M raise
Lantern Pharma reported trial milestones for LP-184 and LP-300 in the same release as a CEO resignation and a roughly $4.0M offering, a mix sponsors and CROs should read carefully.
What Lantern disclosed
On 18 November 2026, Lantern Pharma Inc. reported third-quarter results in an exhibit to a US filing. The release covered four things: clinical progress for its two oncology programs, LP-184 and LP-300; the opening of its first triple-negative breast cancer (TNBC) trial site; the start of HARMONIC Part 2 in Taiwan; and a roughly $4.0M offering. It also said the CEO has resigned.
The record we have is a summary of that release. It does not say which program the TNBC site belongs to or how many sites are planned. It also gives no enrollment figures and no efficacy or safety data. The summary does not cover the offering's terms or who will lead the company next, and we have not assumed either. Readers should check the primary filing for those details.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Sources this analysis is based on
- Lantern Pharma opens first TNBC trial site, starts HARMONIC Part 2 in Taiwan; CEO resigns Lantern Pharma Inc. · Wed 18 Nov 2026
- Teleflex recalls PICC kits and spring-wire guides over coating detachment risk, Health Canada reports Health Canada · Wed 18 Nov 2026
- Health Canada: Raz Design recalls shower commode chairs over seats that can break Health Canada · Wed 18 Nov 2026
- Luxembourg launches national campaign on appropriate antibiotic use for European Antibiotic Awareness Day Luxembourg Health Directorate · Wed 18 Nov 2026
- ANSM bans direct furosemide sales to pharmacies and allows compounded capsules amid shortage ANSM · Wed 18 Nov 2026
- ANSM bans direct lab sales of furosemide to pharmacies as shortage seen lasting into 2027 ANSM · Wed 18 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
Tablo power cord overheating alert shows how a simple instruction change becomes a PV control
FDA's early alert on Outset Medical's Tablo cords is a reminder that use-instruction updates depend on reporting, user follow-through and a clear view of what is still unknown.
EEA Decision 191/2026 extends six EU feed additive acts to EEA EFTA markets, minus Liechtenstein
The EEA Joint Committee has added six feed additive acts, including a monensin sodium renewal and a Duddingtonia flagrans approval, to Annex I. Market access teams should read it as a lesson in how EU rules reach EEA markets.
Prescriber fraud plea and a week of enforcement signals: what QA and compliance should take from it
A Missouri physician and spouse admitted drug-prescribing and health care fraud conspiracies; alongside ANSM, BfArM and OIG actions, the day shows how oversight reaches every link in the chain.